Estrogen and Diabetes
| Status: | Recruiting |
|---|---|
| Conditions: | Diabetes, Diabetes |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | 18 - 40 |
| Updated: | 7/13/2018 |
| Start Date: | April 17, 2018 |
| End Date: | May 1, 2024 |
| Contact: | Maire Rose Bieck, MS |
| Email: | mbieck@augusta.edu |
| Phone: | 706-721-5483 |
Estrogen-Mediated Impairments of Vascular Health in Diabetes
Diabetes has recently been referred to as "the epidemic of the 21st century". The reason why
women with type 1 diabetes have a 2-3 fold greater risk of cardiovascular disease (CVD)
compared to men with type 1 diabetes is unknown.The purpose of this study is to investigate
whether or not estrogen contributes to vascular dysfunction in premenopausal women with
diabetes.
women with type 1 diabetes have a 2-3 fold greater risk of cardiovascular disease (CVD)
compared to men with type 1 diabetes is unknown.The purpose of this study is to investigate
whether or not estrogen contributes to vascular dysfunction in premenopausal women with
diabetes.
Inclusion Criteria:
- Both men and premenopausal
- Normal menstrual cycle interval of 25-35 days for at least 3 previous cycles
- All races
- Clinical diagnosis of insulin-dependent type 1 diabetes (patients only)
Exclusion Criteria:
- Clinical diagnosis of hepatic, cardiovascular, or renal disease
- Uncontrolled Diabetes (HbA1c>9%)
- Diabetic complications (i.e. macrovascular, microvascular, or autonomic)
- Proteinuria
- Uncontrolled Hypertension (>140/90 mmHg on therapy)
- Hormonal use of birth control (past 3 months)
- Pregnancy
- Oligomenorrhea
- Direct vasoactive medications (i.e. nitrates)
- Anti-estrogens (i.e. SERMs)
- Plycystic ovarian syndrome (defined by NIH guidelines-hyperandrogenic anovulation)
- Undetectable Anti-Mullerian Hormone (AMH) following screening
We found this trial at
2
sites
Click here to add this to my saved trials
Click here to add this to my saved trials